0 items | $0.00

HB 20 years

SLB 2014 banner ad


Nitrotyrosine IHC sections

Rat Complement

Quick order

    Product added to cart.

    Latest Hycult Biotech news


    New products

    • YKL-40, Human, mAb mAY

      YKL-40, Human, mAb mAY

      Antibody mAY is capable of binding native as well as recombinant YKL-40 and is capable to inhibit tube formation of microvascular endothelial cells in vitro. The antibody also blocks MAPK signalling via VEGFR2.
    • TLR4, Human, mAb 4D9

      TLR4, Human, mAb 4D9

      The monoclonal antibody 4D9 reacts with the Toll-like receptor 4 (TLR4, CD284). The monoclonal antibody 4D9 reacts with the extracellular part of the receptor. A few studies report the existing of soluble TLR4. This antibody should be able to recognize this protein.
    Want to stay informed about our products? Sign up for our newsletter:
    About Hycult Biotech

    Hycult Biotech

    About Hycult Biotech

    Since 1994, Hycult Biotech designs, develops, produces and markets antibodies, antibody based products and more specifically immunoassays for innate immunity and directly related fields, with an emphasis on complement, neutrophil proteins, TLR, scavenger receptors and acute phase proteins.

    Furthermore, we have a strong interest in progressing research in the area of inflammation and cell damage caused by pathogens or oxidation factors.

    "Hycult Biotech’s mission and strategy is to advance insight in innate immunity related diseases, for the benefit of individuals and their quality of life."

    As a leader within focused fields of immunology and cell biology, we develop products for the life sciences and in accordance with our mission it is our ambition to facilitate the transition of these products from research use into diagnostic testing.

    Many of our reagents are developed in close cooperation with scientists worldwide. Hycult Biotech has built a strong network with over 40 close scientific collaborations with leading international research institutes.

    We contribute to numerous projects and as a result, can continuously offer early access to... Read more »